• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

Methoxyresorufin Inhibitor

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5757449

MBS5757449 is an inhibitor targeting Methoxyresorufin. fluorometric substrate of cytochrome P450 More details

Product Documentation
PDF
Sample Manual Insert View PDF
PDF
Testing Data View PDF
PDF
Certificate of Analysis (COA) View PDF
PDF
QC Report View PDF
PDF
Material Safety Data Sheet View PDF
PDF
Technical Datasheet View PDF
PDF
Protocol View PDF

Product Overview

Online Datasheet in PDF
Product Name
Methoxyresorufin, Inhibitor
Full Product Name
Methoxyresorufin
Form/Format
Solid. Powder
Purity/Purification
98.00%
Preparation and Storage
Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent
Molecular Weight
227.22
Solubility
DMSO: <1mg/mL
(<1mg/ml refers to the product slightly soluble or insoluble)
Formula
C13H9NO3
SMILES
O=C1C=C2OC3=CC(OC)=CC=C3N=C2C=C1
CAS Number
5725-89-3

Product References and Citations for Methoxyresorufin, inhibitor

Klunk W E, Backsai B J, Mathis C A, et al. Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. Journal of Neuropathology & Experimental Neurology, 2002, 61(9): 797-805.
Klunk W E, Backsai B J, Mathis C A, et al. Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. Journal of Neuropathology & Experimental Neurology, 2002, 61(9): 797-805.
Meilandt W J, Maloney J A, Imperio J, et al. Characterization of the selective in vitro and in vivo binding properties of crenezumab to oligomeric Abeta. Alzheimer's Research & Therapy, 2019, 11(1): 97.
Meilandt W J, Maloney J A, Imperio J, et al. Characterization of the selective in vitro and in vivo binding properties of crenezumab to oligomeric Abeta. Alzheimer's Research & Therapy, 2019, 11(1): 97.
Jung C K, Keppler K, Steinbach S, et al. Fibrillar amyloid plaque formation precedes microglial activation. PLoS One, 2015, 10(3): e0119768.
Jung C K, Keppler K, Steinbach S, et al. Fibrillar amyloid plaque formation precedes microglial activation. PLoS One, 2015, 10(3): e0119768.

Other Notes

Small volumes of Methoxyresorufin, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000